CN105944104A - Pharmaceutical composition for treating digestive tract ulcer - Google Patents
Pharmaceutical composition for treating digestive tract ulcer Download PDFInfo
- Publication number
- CN105944104A CN105944104A CN201610437162.0A CN201610437162A CN105944104A CN 105944104 A CN105944104 A CN 105944104A CN 201610437162 A CN201610437162 A CN 201610437162A CN 105944104 A CN105944104 A CN 105944104A
- Authority
- CN
- China
- Prior art keywords
- flos caryophylli
- cortex cinnamomi
- preparation
- cassia oil
- bisfentidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 44
- 231100000397 ulcer Toxicity 0.000 title claims abstract description 44
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 59
- 239000003814 drug Substances 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 23
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 239000003921 oil Substances 0.000 claims description 109
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 105
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 105
- 239000007901 soft capsule Substances 0.000 claims description 59
- 241000628997 Flos Species 0.000 claims description 44
- 229960000620 ranitidine Drugs 0.000 claims description 34
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 34
- FXJAOWANXXJWGJ-UHFFFAOYSA-N n-[4-(2-methyl-1h-imidazol-5-yl)phenyl]-n'-propan-2-ylmethanimidamide Chemical compound C1=CC(NC=NC(C)C)=CC=C1C1=CN=C(C)N1 FXJAOWANXXJWGJ-UHFFFAOYSA-N 0.000 claims description 25
- 229950002342 bisfentidine Drugs 0.000 claims description 24
- 229960001380 cimetidine Drugs 0.000 claims description 24
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 24
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 24
- 239000008187 granular material Substances 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 16
- 229960004872 nizatidine Drugs 0.000 claims description 13
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 claims description 13
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 12
- 239000005770 Eugenol Substances 0.000 claims description 12
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 12
- 229960002217 eugenol Drugs 0.000 claims description 12
- 239000000341 volatile oil Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 9
- 229940117916 cinnamic aldehyde Drugs 0.000 claims description 9
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 claims description 8
- SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 6
- 229960001596 famotidine Drugs 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 229960003320 roxatidine Drugs 0.000 claims description 6
- 239000006196 drop Substances 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 229920001875 Ebonite Polymers 0.000 claims 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims 1
- 235000019082 Osmanthus Nutrition 0.000 claims 1
- 241000333181 Osmanthus Species 0.000 claims 1
- 235000013372 meat Nutrition 0.000 claims 1
- 244000223014 Syzygium aromaticum Species 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 description 106
- 238000000034 method Methods 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 239000002775 capsule Substances 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 21
- 241000700159 Rattus Species 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 17
- 208000007107 Stomach Ulcer Diseases 0.000 description 16
- 201000005917 gastric ulcer Diseases 0.000 description 16
- 210000002784 stomach Anatomy 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 12
- 229920000053 polysorbate 80 Polymers 0.000 description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 11
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000013558 reference substance Substances 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 229960004756 ethanol Drugs 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000890 drug combination Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 238000001256 steam distillation Methods 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- -1 correctives Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000000205 computational method Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229940060184 oil ingredients Drugs 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000012109 statistical procedure Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 101150056637 Hrh2 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 229950005162 benexate Drugs 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pharmaceutical composition for treating a digestive tract ulcer. The pharmaceutical composition comprises a clove and cortex cinnamomi composition, a H2 receptor antagonist and a pharmaceutically acceptable carrier. The invention further provides application of the pharmaceutical composition in preparation of drugs for preventing and/or treating the digestive tract ulcer.
Description
Technical field
The invention belongs to pharmaceutical field, be specifically related to Flos Caryophylli, Cortex Cinnamomi and with the making of bisfentidine
Compositions.
Background technology
Peptic Ulcers is a kind of common digestive tract disease, can betide esophagus, stomach or duodenum.Stomach is burst
Infections is digestive system common disease, frequently-occurring disease, and its typical performance is hungry belch uncomfortable, glutted, pantothenic acid
Or the chronic middle Upper abdominal pain of timing, visible melena and hematemesis time serious after the meal.The traditional Chinese medical science thinks gastric ulcer
Belong to " insufficiency of the spleen ", " insufficiency of stomach ", " Deficiency and coldness of spleen and stomach ", " gastric abscess ", " acid regurgitation ", " regurgitation ", " vomiting "
Deng category.
Bisfentidine can be combined with histamine H2-receptor highly selectively, competitively antagonizing histamine
The gastric acid secretion caused after being combined with H2 receptor, produces Acidinhibitor.Bisfentidine can effectively press down
Gastric acid secretion processed, for the treatment of peptic ulcer.Bisfentidine includes cimetidine, thunder Buddhist nun
For fourth, nizatidine, famotidine, roxatidine etc..
Prior art there is no about Flos Caryophylli, Cortex Cinnamomi preparation, or Flos Caryophylli extract and Cortex Cinnamomi extract, with
Bisfentidine compositions or the report of combination medicine, and the fourth cassia oil system such as fourth cassia oil soft capsule
Agent treats ulcer or the report of gastric ulcer with bisfentidine compositions or combination medicine.
Summary of the invention
It is an object of the present invention to provide a kind of pharmaceutical composition treating digestive tract ulcer；
Further object is that this pharmaceutical composition of offer is at preparation treatment digestive tract ulcer medicine
Purposes in thing；
Third object of the present invention is to provide a kind of medicine box treating digestive tract ulcer.
It is an object of the invention to be achieved through the following technical solutions:
As one aspect of the present invention, it is provided that a kind of pharmaceutical composition, said composition by active component and
Selectable pharmaceutically acceptable carrier is made, wherein the raw material of active component by Flos Caryophylli, Cortex Cinnamomi and
Bisfentidine forms.Wherein may select and refer to that said composition can be without pharmaceutically acceptable
Carrier, is only made up of active component.
Described Flos Caryophylli, the gross weight of Cortex Cinnamomi are (0.25～4) with the weight ratio of bisfentidine: 1；
It is preferably (1～4): 1；It is preferably 4:1 or 1:1.
Described bisfentidine include cimetidine, ranitidine, nizatidine, famotidine,
Any one or two kinds of in roxatidine or two or more combination.
Flos Caryophylli in described active component, the active part of Cortex Cinnamomi can select Flos Caryophylli, Cortex Cinnamomi pulverizing to obtain,
Or Flos Caryophylli, Cortex Cinnamomi are individually or the extract that obtains of united extraction；Preferably Flos Caryophylli, Cortex Cinnamomi are extracted respectively and wave
Hair oil, and obtain fourth cassia oil and Flos Caryophylli, Cortex Cinnamomi mixed extraction after Flos Caryophylli volatile oil, Cortex Cinnamomi volatile oil mixing
The volatile oil that obtains (in this patent Flos Caryophylli, Cortex Cinnamomi are individually extracted mixed volatile oil and Flos Caryophylli,
The volatile oil that Cortex Cinnamomi mixed extraction obtains is fourth cassia oil).
Above-mentioned fourth cassia oil, i.e. fourth cassia oil extract, be with Flos Caryophylli, Cortex Cinnamomi for raw material extracting method routinely
The extract with volatile oil as main component extracted；Described Flos Caryophylli, the weight ratio of Cortex Cinnamomi are (0.2～5):
1, preferably 1:1；Described general extraction methods includes steam distillation, extraction, circumfluence method, oozes
Filter method, ultrasonic method etc.；Described Extraction solvent includes that water or organic solvent, described organic solvent include oil
Ether, ethyl acetate, n-butyl alcohol, acetone, ethanol or methanol；Preferably steam distillation or with petroleum ether
Extraction.
Preferably, in described fourth cassia oil, by weight percentage, the total content of eugenol and cinnamic aldehyde is big
In or equal to 50%, preferably 50%-95%, more preferably 61%-85%, the most preferably
61%, 85%.
Described pharmaceutical composition can be prepared as oral formulations, as tablet, hard capsule, soft capsule,
Granule, effervescent, suspensoid, powder, powder, drop pill, microsphere, oral liquid etc..
As another aspect of the present invention, present invention also offers aforementioned pharmaceutical compositions in preparation treatment
Purposes in digestive tract ulcer medicine.
As another aspect of the present invention, invention further provides a kind of medicine box, described medicine box bag
Include Flos Caryophylli Cortex Cinnamomi composite preparation and the bisfentidine of therapeutically effective amount.
Described bisfentidine include cimetidine, ranitidine, nizatidine, famotidine,
Any one or two or more compositions in roxatidine.
Described Flos Caryophylli Cortex Cinnamomi composite preparation is to be pulverized, by Flos Caryophylli, Cortex Cinnamomi, the compositions that obtains or extraction obtains
Extract be prepared as tablet, hard capsule, soft capsule, granule, effervescent, suspensoid,
The peroral dosage forms such as powder, powder, drop pill, microsphere or oral liquid；Preferably Flos Caryophylli, Cortex Cinnamomi individually or merges
Extract the soft capsule that the fourth cassia oil obtained is made.
Above-mentioned fourth cassia oil, i.e. fourth cassia oil extract, be with Flos Caryophylli, Cortex Cinnamomi for raw material extracting method routinely
The extract with volatile oil as main component extracted；Described Flos Caryophylli, the weight ratio of Cortex Cinnamomi are (0.2～5):
1, preferably 1:1；Described general extraction methods includes steam distillation, extraction, circumfluence method, oozes
Filter method, ultrasonic method etc.；Described Extraction solvent includes that water or organic solvent, described organic solvent include oil
Ether, ethyl acetate, n-butyl alcohol, acetone, ethanol or methanol；Preferably steam distillation or with petroleum ether
Extraction.
Preferably, in described fourth cassia oil, by weight percentage, the content of eugenol and cinnamic aldehyde is more than
Or equal to 50%, preferably 50%-95%, more preferably 61%-85%, the most preferably 61%,
85%.
Bisfentidine of the present invention, as ranitidine, cimetidine can be used for treating 12 fingers
The disease such as intestinal ulcer, gastric ulcer, but liver is had certain toxicity, Liver and kidney function infull patient be cautious use of,
In addition there is the side effect such as absorption reducing vitamin B12.
" effective dose " of the present invention or " therapeutically effective amount " refer to avirulence, but needed for the offer of q.s
The medicine of effect or medicament.In the therapeutic alliance of the present invention, in associating " effective dose " of a kind of composition
Refer to that this composition effectively provides the amount of required effect with other ingredient combination when applying." effective dose " can be because of
The difference of experimenter and different, according to age and individual ordinary circumstance, specific active medicine etc..
Therefore, it is not possible to always refer to accurate " effective dose ", but, in any individual case suitably " effectively
Amount " experimental technique of routine can be applied to measure by those of ordinary skill in the art.
" treatment " of the present invention refers to that the order of severity of symptom alleviates and/or frequency reduces, symptom and/or draw
Play the elimination of reason of symptom, the generation of symptom and/or they cause the prevention of the reason of symptom, infringement
Improve or correct.
" administering drug combinations " of the present invention refers to give object with certain dosage regimen by drug regimen, as
Flos Caryophylli Cortex Cinnamomi compositions and bisfentidine are with different size unit dose simultaneously, give respectively or successively
Medicine.
Pharmaceutically suitable carrier of the present invention include filler, disintegrating agent, lubricant, suspending agent, binding agent,
Sweeting agent, correctives, preservative, substrate etc..Filler includes: starch, pregelatinized Starch, lactose,
Mannitol, chitin, microcrystalline Cellulose, sucrose etc.；Disintegrating agent includes: starch, pregelatinized Starch,
Microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, friendship
Connection sodium carboxymethyl cellulose etc.；Lubricant includes: magnesium stearate, sodium lauryl sulphate, Pulvis Talci,
Silicon dioxide etc.；Suspending agent includes: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxyl
Propyl methocel etc.；Binding agent includes: starch slurry, polyvinylpyrrolidone, hydroxypropyl methyl are fine
Dimension element etc.；Sweeting agent includes: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.；Rectify
Taste agent includes: sweeting agent and various essence；Preservative includes: parabens, benzoic acid, sodium benzoate,
Sorbic acid and its esters, benzalkonium bromide, fixed, the eucalyptus oil of acetic acid chloroethene etc.；Substrate includes: PEG6000,
PEG4000, insect wax etc..
As another aspect of the present invention, the present invention further provides, a kind of Chinese medicine composition is in preparation
Application in potentiation bisfentidine treatment digestive tract ulcer medicine, the raw material of described Chinese medicine composition
Medicine is made up of Flos Caryophylli, Cortex Cinnamomi, and Flos Caryophylli, the weight ratio of Cortex Cinnamomi are (0.2～5): 1.
Described Chinese medicine composition can be prepared as clinically-acceptable dosage form, and preparation method includes Flos Caryophylli Cortex Cinnamomi
Pulverize the compositions that obtains or tablet that extract that extraction obtains is prepared as, hard capsule, soft capsule,
The peroral dosage forms such as granule, effervescent, suspensoid, powder, powder, drop pill, microsphere or oral liquid.
Preferably Flos Caryophylli, Cortex Cinnamomi are individually or the soft capsule made of the fourth cassia oil that obtains of united extraction.Described fourth cassia oil,
I.e. fourth cassia oil extract, is to be with volatile oil with Flos Caryophylli, Cortex Cinnamomi for what raw material extracting method routinely extracted
The extract of main component；Described Flos Caryophylli, the weight ratio of Cortex Cinnamomi are (0.2～5): 1, preferably 1:1；
Described general extraction methods includes steam distillation, extraction, circumfluence method, percolation, ultrasonic method etc.；
Described Extraction solvent includes that water or organic solvent, described organic solvent include petroleum ether, ethyl acetate, just
Butanol, acetone, ethanol or methanol；Preferably steam distillation or petroleum ether extraction.Preferably, institute
Stating in fourth cassia oil, by weight percentage, the total content of eugenol and cinnamic aldehyde is more than or equal to 50%,
Preferably 50%-95%, more preferably 61%-85%, the most preferably 61%, 85%.
The present invention use the combination of Flos Caryophylli Cortex Cinnamomi compositions (preferably fourth cassia oil) and bisfentidine/
Pharmaceutical composition, on the one hand the treatment for digestive tract ulcer achieves the effect of Synergistic, significantly carries
High to digestive tract ulcer, such as the therapeutic effect of gastric ulcer；On the other hand can effectively reduce ranitidine,
The using dosage of cimetidine, reduces the bisfentidine side effect to Liver and kidney, also reduces simultaneously
The using dosage of fourth cassia oil or fourth cassia oil soft capsule etc..The combination medicine of the present invention and pharmaceutical composition
While realizing therapeutic effect Synergistic, can effectively reduce drug use dosage, alleviate medicine pair and make
With, reduce treatment drug expenditure, achieve unforeseeable technological progress.
Fourth cassia oil soft capsule and the main representative thing cimetidine of bisfentidine, ranitidine combination
After there is significant anti-peptic ulcer effect, be better than alone group (p < 0.01 or p < 0.05), and energy
Significantly reduce the dosage of fourth cassia oil soft capsule and bisfentidine.Fourth cassia oil soft capsule of the present invention and H2
The combination medicine of receptor antagonist has the effect of Synergistic for gastric ulcer treatment.
Detailed description of the invention
The preparation of embodiment 1 fourth cassia oil
Taking Flos Caryophylli 375g, Cortex Cinnamomi 375g, add 8 times amount water, water proof distills 8 hours, collects volatile oil, cold
Hide 24 hours, remove moisture, 36.0ml fourth cassia oil the most processed.After testing, eugenol and Cortex cinnamomi japonici (Ramulus Cinnamomi) in extract
The total content of aldehyde accounts for the 85% of fourth cassia oil.
Eugenol detection method:
Chromatographic condition: PEG-20M fused-silica capillary column (25m × 0.20mm × 0.33 μm), column temperature
175 DEG C, fid detector, carrier gas: N2, flow velocity: 1ml min-1Split sampling, split ratio: 45:1,
Sample size 1 μ L.
The preparation of reference substance solution: take eugenol reference substance about 10mg, accurately weighed, put in 5mL measuring bottle,
Accurate addition n-hexane dissolution is also diluted to scale, shakes up, as reference substance solution.
The preparation of need testing solution: the fourth cassia oil about 50mg of Example 1 preparation, accurately weighed, put 25mL
In measuring bottle, accurate addition n-hexane dissolution is also diluted to scale, shakes up, as need testing solution.
The preparation of internal standard liquid: take biphenyl 10mg, puts in 25mL measuring bottle, and accurate addition n-hexane dissolution is also
It is diluted to scale, shakes up, as inner mark solution.
The investigation of linear relationship: precision weighs eugenol reference substance 102.70mg, puts in 10mL volumetric flask,
Add n-hexane dissolution and be diluted to scale, respectively precision measure 0.5,1.0,2.0,3.0,5.0mL is in 25mL
Volumetric flask in, add normal hexane and be diluted to scale.Precision draws 1.0 μ L, injection gas chromatography instrument respectively
In, it is measured by above-mentioned chromatographic condition.With injection eugenol amount (X) as abscissa, corresponding reference substance
Peak area (y) is vertical coordinate, carries out linear regression, obtains regression equation.
Need testing solution is detected by GC conditions, brings detected value into regression equation calculation and obtain
Eugenol content in the fourth cassia oil of embodiment 1 preparation.
Cinnamic aldehyde detection method:
Chromatographic condition: 2m × 3mm glass column (Japan's Shimadzu) fixative: 2%OV-17 carrier: 60～80
Mesh chromosorbw (AW-DMCS), carrier: High Purity Nitrogen, flow velocity: 50ml/min, column temperature: 175 DEG C
Temperature of vaporization chamber 220 DEG C, sensing chamber's temperature 180 DEG C, detector FID.
The preparation of reference substance solution: precision weighs cinnamic aldehyde 17.5ml in 25ml measuring bottle, CC14Dissolve
Dissolve and be diluted to scale, shaking up, as reference substance solution.
The preparation of need testing solution: precision weigh embodiment 1 preparation fourth cassia oil 25mg in 50ml measuring bottle,
Use CCl4Dissolve and be diluted to scale, shaking up, as reference substance solution.
Linear relationship is investigated: 6 10ml measuring bottles numbering, be sequentially added into reference substance solution 0.5,1.0,2.0,
3.0,4.0,5.0ml, use CCl4Dilute mutual scale, shake up.Precision draws 1.0 μ L respectively, injects gas
In chromatography, as described in step 2, chromatographic condition detects, and with concentration (X), peak area (Y) is carried out line
Property return, obtain regression equation.
Need testing solution is detected by GC conditions, brings detected value into regression equation calculation and obtain
Determination of Cinnamaldehyde in the fourth cassia oil of embodiment 1 preparation.
The preparation of embodiment 2 fourth cassia oil
In 1:1 ratio, take Flos Caryophylli, Cortex Cinnamomi medical material totally 750 grams, add 6 times amount petroleum ether 50 DEG C extraction 4h,
Filtering, medicinal residues add 4 times amount petroleum ether 50 DEG C extraction 4h again, filter, merge petroleum ether extract, reclaim
Petroleum ether, 46.8ml fourth cassia oil the most processed.After testing, in extract, the total content of eugenol and cinnamic aldehyde accounts for
The 61% of fourth cassia oil.Detection method is with reference to embodiment 1.
The preparation of embodiment 3 fourth cassia oil soft capsule
The fourth cassia oil 3.6ml (25 DEG C of relative densities are 1.10g/ml) of Example 1 preparation and 36.4ml Semen sojae atricolor
Oil mixing, standby.Take gelatin 15g, glycerol 6g, simple syrup 1g, add deionized water 15g mixing, heating
To 60～70 DEG C, it is incubated 0.5 hour, adds methyl parahydroxybenzoate 0.015g, P-hydroxybenzoic acid second
Ester 0.0075g, stirring, evacuation, 70 DEG C are incubated 20 minutes, make capsule material.Take fourth cassia oil and soybean oil
Mixture, with capsule material use pressing make soft capsule, inspection, subpackage, obtain soft capsule 100,
Every dress 0.4g, containing fourth cassia oil about 0.04g).
The preparation of embodiment 4 fourth cassia oil tablet
The fourth cassia oil 3ml of Example 2 preparation, adds micropowder silica gel 2.5mg, lactose 5.5mg, microcrystalline cellulose
Element 5.3mg, Icing Sugar 3.0mg, pelletize with 10%PVP-k30 aqueous solution, additional low substituted hydroxy-propyl fiber
Element 0.5mg and magnesium stearate 0.2mg, tabletting, to obtain final product.
The preparation of embodiment 5 fourth cassia oil granule
The fourth cassia oil 5ml of Example 1 preparation, and be dissolved in a small amount of ethanol, standby.Take 40g β-ring to stick with paste
Essence, adds 300ml distilled water, and heating in water bath dissolves, and it is molten that temperature is down to add volatile oil ethanol when 35 DEG C
Liquid, mix homogeneously, ultrasonic inclusion 30min, refrigerated overnight, sucking filtration, it is deposited in 38 DEG C of cold drying,
Obtain volatile oil beta cyclodextrin inclusion complex.Benexate Hydrochloride is mixed with appropriate dextrin, uses 90% second
Alcohol is wetting agent soft material, crosses 20 mesh sieves and carries out wet granulation, and 65 DEG C are dried, and granulate to obtain final product.
The preparation of embodiment 6 fourth cassia oil soft capsule
The fourth cassia oil 16g of Example 1 preparation mixes with 64g soybean oil, standby.Take gelatin 18g, glycerol
5g, simple syrup 1g, add deionized water 15g mixing, be heated to 65 DEG C, be incubated 0.5 hour, add hydroxyl
Yl benzoic acid methyl ester 0.02g, ethylparaben 0.001g, stirring, evacuation, 75 DEG C of insulations 20
Minute, make capsule material.Take the mixture of fourth cassia oil and soybean oil, use pressing to make flexible glue by capsule material
Capsule, inspection, subpackage, obtain soft capsule 100, every dress 0.4g, containing fourth cassia oil about 0.16g)
The preparation of the combination medicine/composite packaging medicine box of embodiment 7 fourth cassia oil soft capsule and ranitidine
The fourth cassia oil soft capsule of Example 6 preparation, every about 0.16g Han fourth cassia oil.
Ranitidine Capsules, every contains ranitidine 0.15 gram.
Composite packaging form: containing fourth cassia oil soft capsule 90, Ranitidine Capsules 30 in this packaging.
Embodiment 8 fourth cassia oil and the compound tablet of cimetidine
Prepare fourth cassia oil 100g by embodiment 1 method, and take cimetidine crude drug 100g, standby.
With reference to the method for embodiment 5, it is only that 20 mesh sieves in embodiment five are replaced with 50 mesh sieves, preparation β-
The fourth cassia oil granule of cyclodextrin inclusion compound.By fourth cassia oil granule and cimetidine crude drug and appropriate medicinal shallow lake
Powder, microcrystalline Cellulose, silicon dioxide mix, and are pressed into 500.
Embodiment 9 fourth cassia oil and the compound capsule of cimetidine
Prepare fourth cassia oil 300g by embodiment 1 method, and take cimetidine crude drug 200g, routinely
Preparation process makes capsule.
Embodiment 10 fourth cassia oil and the compound granule of cimetidine
Prepare fourth cassia oil 200g by embodiment 1 method, and take cimetidine crude drug 300g, routinely
Preparation process makes granule.
Embodiment 11 fourth cassia oil and the compound tablet of ranitidine
Prepare fourth cassia oil 100g by embodiment 1 method, and take ranitidine crude drug 100g, standby.
With reference to the method for embodiment 5, it is only that 20 mesh sieves in embodiment five are replaced with 50 mesh sieves, preparation β-
The fourth cassia oil granule of cyclodextrin inclusion compound.By fourth cassia oil granule and ranitidine crude drug and appropriate medicinal shallow lake
Powder, microcrystalline Cellulose, silicon dioxide mix, and are pressed into 500.
Embodiment 12 fourth cassia oil and the compound capsule of ranitidine
Prepare fourth cassia oil 300g by embodiment 1 method, and take ranitidine crude drug 200g, routinely
Preparation process makes capsule.
Embodiment 13 fourth cassia oil and the compound granule of ranitidine
Prepare fourth cassia oil 200g by embodiment 1 method, and take ranitidine crude drug 300g, routinely
Preparation process makes granule.
Embodiment 14 fourth cassia oil and the compound tablet of nizatidine
Prepare fourth cassia oil 100g by embodiment 1 method, and take nizatidine crude drug 100g, standby.
With reference to the method for embodiment 5, it is only that 20 mesh sieves in embodiment five are replaced with 50 mesh sieves, preparation β-
The fourth cassia oil granule of cyclodextrin inclusion compound.By fourth cassia oil granule and nizatidine crude drug and appropriate medicinal shallow lake
Powder, microcrystalline Cellulose, silicon dioxide mix, and are pressed into 500.
Embodiment 15 fourth cassia oil and the compound capsule of nizatidine
Prepare fourth cassia oil 300g by embodiment 1 method, and take nizatidine crude drug 200g, routinely
Preparation process makes capsule.
Embodiment 16 fourth cassia oil and the compound granule of nizatidine
Prepare fourth cassia oil 200g by embodiment 1 method, and take nizatidine crude drug 300g, routinely
Preparation process makes granule.
The treatment to water logging irritability rat gastric ulcer of experimental example 1 present composition
1. experiment material
1.1 medicine
Fourth cassia oil soft capsule (0.4g/ grain): adult's dosage is 6/day, prepares by embodiment 3.
Take soft capsule content, with 1.0% Tween 80 solution preparation, place Refrigerator store standby.
Ranitidine Capsules (Lei Liya) (0.15g/ grain): be grown up one time 1,2 times on the one, tie up Aunar
This (Foshan) pharmaceutical Co. Ltd provides, lot number 120608.Take soft capsule content, use 1.0% Tween 80
Solution is prepared, and places Refrigerator store standby.
Cimitidine Tablets (0.2g/ sheet): one time 1,2 times on the one, limited by Arstwyth (Foshan) pharmacy
Company provides, lot number 120107.Take soft capsule content, with 1.0% Tween 80 solution preparation, place ice
Case saves backup.
Fourth cassia oil soft capsule and cimetidine, and fourth cassia oil soft capsule and ranitidine combination medicine/
The proportioning of pharmaceutical composition is shown in Table 1；Dosage and concentration respectively with fourth cassia oil, ranitidine,
Cimetidine calculates.
1.2 animal
SD rat, male and female half and half, body weight 180-220g, Chengdu University of Traditional Chinese Medicine's Experimental Animal Center carry
Confession, the animal quality certification number is the real dynamic pipe the 7th in river.
2 methods and result
2.1 test method
Select healthy SD rat, body weight 180-220g, be divided into 8 groups by body weight, sex stratified random,
Often 10 animals of group, packet and dosage are shown in Table 1.Each treated animal gastric infusion every day once (dosage
It is shown in Table 1), continuous 15 days, after last administration, fasting 24 hours, freely drank water, is then fixed by animal
On metal cage, it is dipped vertically in 23 ± 0.5 DEG C of water.Immersion depth translation thing xiphoid-process level, after 24 hours
Taking out, dislocation of cervical vertebra is put to death.Opening abdominal cavity, ligation stomach cardia and pylorus also inject in gastral cavity through coat of the stomach
Formalin 8ml of 1%, takes out stomach and immerses in formalin, and within 30 minutes, tailing edge greater gastric curvature is cut open, puts
Measuring gastric mucosa injury area under big mirror, by okabe method, calculate ulcer index, computational methods are as follows.
| Ulcer area (mm2) | 1-12 | 13-25 | 26-37 | 38-45 | >=50 or perforation |
| Ulcer index | 1 | 2 | 3 | 4 | 5 |
Ulcer inhibition percentage=matched group ulcer index-administration group ulcer index/matched group ulcer index × 100%
2.2 experimental result
To each group of experimental result, statistical procedures between organizing, the results are shown in Table 1.
Table 1 on the impact of water logging irritability rat gastric ulcer model (N=10)
Note: compare with model control group*p<0.05、**p<0.01；Compare with fourth cassia oil soft capsule group#p<0.05、##p<0.01。
Table 1 result shows, after administration, and alone group of (fourth cassia oil soft capsule group, Cimitidine Tablets group, thunder
Buddhist nun replaces fourth Capsules group) and the no significant difference (P > 0.05) of model group, and drug combination group (fourth
Cassia oil soft capsule+Cimitidine Tablets 1,2 groups, fourth cassia oil soft capsule+Ranitidine Capsules 1,2 groups) right
Rat water logging stress gastric ulcer significantly inhibits effect (p < 0.01, p < 0.05).Drug combination group and list
Compare by group, there is significant difference (p < 0.01, p < 0.05).
The treatment to pyloric ligation ulcers rat gastric ulcer of experimental example 2 pharmaceutical composition of the present invention
1. experiment material
1.1 medicine
Fourth cassia oil soft capsule (0.4g/ grain): adult's dosage is 6/day, prepares by embodiment 3.
Take soft capsule content, with 1.0% Tween 80 solution preparation, place Refrigerator store standby.
Ranitidine Capsules (Lei Liya) (0.15g/ grain): be grown up one time 1,2 times on the one, by Aunar
Wei Si (Foshan) pharmaceutical Co. Ltd provides, lot number 120608.Take soft capsule content, use 1.0% tween
80 solution preparations, place Refrigerator store standby.
Cimitidine Tablets (0.2g/ sheet): one time 1,2 times on the one, Arstwyth (Foshan) pharmacy have
Limit company provides, lot number 120107.Take soft capsule content, with 1.0% Tween 80 solution preparation, put
Put Refrigerator store standby.
Fourth cassia oil soft capsule and cimetidine, and fourth cassia oil soft capsule and ranitidine combination medicine/
The proportioning of pharmaceutical composition is shown in Table 2；Dosage and concentration respectively with fourth cassia oil, ranitidine,
Cimetidine calculates.
1.2 animal
SD rat, male and female half and half, body weight 180-220g, by Chengdu University of Traditional Chinese Medicine's Experimental Animal Center
Thering is provided, the animal quality certification number is the real dynamic pipe the 7th in river.
2 methods and result
2.1 test method
Select healthy SD rat, body weight 180-220g, be randomly divided into 8 groups by body weight, sex, often group
10 animals, packet and dosage are shown in Table 2.Each treated animal gastric infusion every day once (dosage such as table
Shown in 2), continuous 15 days, after last administration, fasting 48 hours, freely drank water, with ether by animal fiber crops
Liquor-saturated, open abdominal cavity, ligature pylorus.Within postoperative 18 hours, solution takes stomach, injects the formaldehyde of 1% in gastral cavity
Solution 8ml, takes out stomach and immerses in formalin, and within 10 minutes, tailing edge greater gastric curvature is cut open, amplifies Microscopic observation
A situation arises for front stomach ulcer, by okabe method, calculates ulcer index, and computational methods are as follows.
| Ulcer area (mm2) | 1-12 | 13-25 | 26-37 | 38-45 | >=50 or perforation |
| Ulcer index | 1 | 2 | 3 | 4 | 5 |
Ulcer inhibition percentage=matched group ulcer index-administration group ulcer index/matched group ulcer index × 100%
2.2 experimental result
To each group of experimental result, statistical procedures between organizing, the results are shown in Table 2.
Table 2 on the impact of pyloric ligation ulcers rat gastric ulcer model (N=10)
Note: compare with model control group*p<0.05、**p<0.01；Compare with fourth cassia oil soft capsule group#p<0.05、##p<0.01。
Table 2 result shows, after administration, and alone group of (fourth cassia oil soft capsule group, Cimitidine Tablets group, thunder
Buddhist nun replaces fourth Capsules group) and the no significant difference (P > 0.05) of model group, and drug combination group (fourth
Cassia oil soft capsule+Cimitidine Tablets 1,2 groups, fourth cassia oil soft capsule+Ranitidine Capsules 1,2 groups) right
Rat pylorus ligation gastric ulcer model has obvious inhibitory action (p < 0.01, p < 0.05).
Acetic acid is burnt the treatment of type rat gastric ulcer by experimental example 3 pharmaceutical composition of the present invention
1. experiment material
1.1 medicine
Fourth cassia oil soft capsule (0.4g/ grain): adult's dosage is 6/day, is obtained by by embodiment 3 preparation
?.Take soft capsule content, with 1.0% Tween 80 solution preparation, place Refrigerator store standby.
Ranitidine Capsules (Lei Liya) (0.15g/ grain): be grown up one time 1,2 times on the one, by Aunar
Wei Si (Foshan) pharmaceutical Co. Ltd provides, lot number 120608.Take soft capsule content, use 1.0% tween
80 solution preparations, place Refrigerator store standby.
Cimitidine Tablets (0.2g/ sheet): one time 1,2 times on the one, Arstwyth (Foshan) pharmacy have
Limit company provides, lot number 120107.Take soft capsule content, with 1.0% Tween 80 solution preparation, put
Put Refrigerator store standby.
Fourth cassia oil soft capsule and cimetidine, and fourth cassia oil soft capsule and ranitidine combination medicine/
The proportioning of pharmaceutical composition is shown in Table 3；Dosage and concentration respectively with fourth cassia oil, ranitidine,
Cimetidine calculates.
1.2 animal
SD rat, male and female half and half, body weight 180-220g, by Chengdu University of Traditional Chinese Medicine's Experimental Animal Center
Thering is provided, the animal quality certification number is the real dynamic pipe the 7th in river.
2 methods and result
2.1 test method
Selecting healthy SD rat, body weight 180-220g, before experiment, fasting 24 hours, freely drinks water,
Under etherization open abdominal cavity, expose stomach, before the acetic acid solution 0.1ml of 20% is injected to glandular stomach portion
Under wall hole body intersection serous coat.Reduction stomach, suturing them.Animal is pressed body weight, property on the 2nd day by Post operation
Other stratified random is divided into 8 groups, often 10 animals of group, and packet and dosage are shown in Table 3.Each treated animal fills every day
Stomach is administered once (dosage is shown in Table 3), continuous 15 days, fasting 24 hours after last administration,
Freely drink water, with excess diethyl ether, Animal Anesthesia is dead, open abdominal cavity, solution takes stomach, by the first of 1%
Aldehyde solution is fixed, and by okabe method, observes and calculates ulcer index, and computational methods are as follows.
| Ulcer area (mm2) | 1-12 | 13-25 | 26-37 | 38-45 | >=50 or perforation |
| Ulcer index | 1 | 2 | 3 | 4 | 5 |
Ulcer inhibition percentage=matched group ulcer index-administration group ulcer index/matched group ulcer index × 100%
2.2 experimental result
To each group of experimental result, statistical procedures between organizing, the results are shown in Table 3.
Table 3 acetic acid is burnt type rat gastric ulcer model impact (N=10)
Note: compare with model control group*p<0.05、**p<0.01；Compare with fourth cassia oil soft capsule group#p<0.05、##p<0.01。
Table 3 result shows, after administration, and alone group of (fourth cassia oil soft capsule group, Cimitidine Tablets group, thunder
Buddhist nun replaces fourth Capsules group) and the no significant difference (P > 0.05) of model group, and drug combination group (fourth
Cassia oil soft capsule+Cimitidine Tablets 1,2 groups, fourth cassia oil soft capsule+Ranitidine Capsules 1,2 groups) right
Rats acetic acid burns type gastric ulcer model and has significant inhibitory action (p < 0.01,0.05), with alone group
Relatively, there is significant difference (p < 0.01,0.05).
Experimental example 4 pharmaceutical composition of the present invention causes the treatment of rat pipe film injury to ethanol
1. experiment material
1.1 medicine
Fourth cassia oil soft capsule (0.4g/ grain): adult's dosage is 6/day, prepares by embodiment 3.
Take soft capsule content, with 1.0% Tween 80 solution preparation, place Refrigerator store standby.
Ranitidine Capsules (Lei Liya) (0.15g/ grain): be grown up one time 1,2 times on the one, by Aunar
Wei Si (Foshan) pharmaceutical Co. Ltd provides, lot number 120608.Take soft capsule content, use 1.0% tween
80 solution preparations, place Refrigerator store standby.
Cimitidine Tablets (0.2g/ sheet): one time 1,2 times on the one, Arstwyth (Foshan) pharmacy have
Limit company provides, lot number 120107.Take soft capsule content, with 1.0% Tween 80 solution preparation, put
Put Refrigerator store standby.
Fourth cassia oil soft capsule and cimetidine, and fourth cassia oil soft capsule and ranitidine combination medicine/
The proportioning of pharmaceutical composition is shown in Table 4；Dosage and concentration respectively with fourth cassia oil, ranitidine,
Cimetidine calculates.
1.2 animal
SD rat, male and female half and half, body weight 180-220g, by Chengdu University of Traditional Chinese Medicine's Experimental Animal Center
Thering is provided, the animal quality certification number is the real dynamic pipe the 7th in river.
2 methods and result
2.1 test method
Select healthy SD rat, body weight 180-220g, be divided into 8 groups by body weight, sex stratified random,
Often 10 animals of group, packet and dosage are shown in Table 5.Each treated animal gastric infusion every day once (dosage
It is shown in Table 4), continuous 15 days, after last administration, fasting 48 hours, freely drank water.Fill during experiment
Taking dehydrated alcohol (1ml/ is only), after one hour, animal is put to death in dislocation of cervical vertebra, opens abdominal cavity, and solution takes stomach,
Fixing with the formalin of 1%, within 30 minutes, tailing edge greater gastric curvature is cut open, amplifies Microscopic observation stomach ulcer
A situation arises, by okabe method, calculates ulcer index, and computational methods are as follows
| Ulcer area (mm2) | 1-12 | 13-25 | 26-37 | 38-45 | >=50 or perforation |
| Ulcer index | 1 | 2 | 3 | 4 | 5 |
Ulcer inhibition percentage=matched group ulcer index-administration group ulcer index/matched group ulcer index × 100%
2.2 experimental result
To each group of experimental result, statistical procedures between organizing, the results are shown in Table 4.
Table 4 on ethanol cause rat pipe film injury model impact (N=10)
Note: compare with model control group*p<0.05、**p<0.01；Compare with fourth cassia oil soft capsule group#p<0.05、##p<0.01。
Table 4 result shows, after administration, alone group with the no significant difference (P > 0.05) of model group,
And drug combination group (fourth cassia oil soft capsule+Cimitidine Tablets 1,2 groups, fourth cassia oil soft capsule+thunder Buddhist nun replace
Fourth capsule 1,2 groups) to ethanol cause rat pipe film injury model have significant protective effect (p < 0.01,
0.05).Drug combination group compares with alone group, has significant difference (p < 0.011,0.05).
Claims (10)
1. the pharmaceutical composition treating digestive tract ulcer, it is characterised in that said composition is by activity
Composition and selectable pharmaceutically acceptable carrier are made, and wherein the raw material of active component is by Flos Caryophylli, meat
Osmanthus and bisfentidine composition.
2. pharmaceutical composition as claimed in claim 1, it is characterised in that described Flos Caryophylli, Cortex Cinnamomi
Weight ratio is (0.2～5): 1；Flos Caryophylli, the gross weight of Cortex Cinnamomi with the weight ratio of bisfentidine are
(0.25～4): 1；It is preferably (1～4): 1；More preferably 1:1 or 4:1.
3. pharmaceutical composition as claimed in claim 1, it is characterised in that described bisfentidine
Any one in cimetidine, ranitidine, nizatidine, famotidine, roxatidine or two
Kind or two or more combinations.
4. pharmaceutical composition as claimed in claim 1, it is characterised in that wherein Flos Caryophylli, Cortex Cinnamomi are straight
Connect as active component, or Flos Caryophylli, Cortex Cinnamomi individually or the extract that obtains of united extraction is as active component；
Preferably Flos Caryophylli, Cortex Cinnamomi are individually or the volatile oil that obtains of united extraction is as active component.
5. pharmaceutical composition as claimed in claim 4, it is characterised in that in described fourth cassia oil, with
The total content of percentage by weight meter, eugenol and cinnamic aldehyde is more than or equal to 50%, preferably 50%-95%,
More preferably 61%-85%, the most preferably 61% or 85%.
6. a Chinese medicine composition is in preparation potentiation bisfentidine treatment digestive tract ulcer medicine
Application, the crude drug of described Chinese medicine composition is made up of Flos Caryophylli, Cortex Cinnamomi, and Flos Caryophylli, the weight ratio of Cortex Cinnamomi are
(0.2～5): 1；Preferably bisfentidine preparation selected from cimetidine, ranitidine, nizatidine,
The preparation that any one or two kinds of and two or more combinations in famotidine, roxatidine is made.
7. a medicine box, it is characterised in that described medicine box includes the Flos Caryophylli Cortex Cinnamomi combination of therapeutically effective amount
Thing preparation and bisfentidine preparation.
8. medicine box as claimed in claim 7, it is characterised in that described bisfentidine preparation selects
Any one or two kinds of in cimetidine, ranitidine, nizatidine, famotidine, roxatidine
And the preparation that two or more combinations is made.
9. medicine box as claimed in claim 7, it is characterised in that described Flos Caryophylli Cortex Cinnamomi composite preparation
It is to be pulverized, by Flos Caryophylli, Cortex Cinnamomi, the compositions that obtains or tablet that extract that extraction obtains is prepared as, ebonite
Wafer, soft capsule, granule, effervescent, suspensoid, powder, powder, drop pill, microsphere or mouth
Take liquid；Described Flos Caryophylli Cortex Cinnamomi composite preparation preferably Flos Caryophylli, Cortex Cinnamomi are individually or the fourth that obtains of united extraction
Soft capsule prepared by cassia oil.
10. medicine box as claimed in claim 9, it is characterised in that in described fourth cassia oil, with weight hundred
The total content of proportion by subtraction meter, eugenol and cinnamic aldehyde is more than or equal to 50%, preferably 50%-95%, enters
One step is preferably 61%-85%, and the most preferably 61%, 85%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610437162.0A CN105944104B (en) | 2016-06-17 | 2016-06-17 | A kind of pharmaceutical composition for treating digestive tract ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610437162.0A CN105944104B (en) | 2016-06-17 | 2016-06-17 | A kind of pharmaceutical composition for treating digestive tract ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105944104A true CN105944104A (en) | 2016-09-21 |
| CN105944104B CN105944104B (en) | 2018-12-14 |
Family
ID=56906041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610437162.0A Active CN105944104B (en) | 2016-06-17 | 2016-06-17 | A kind of pharmaceutical composition for treating digestive tract ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105944104B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108653381A (en) * | 2018-07-11 | 2018-10-16 | 合肥华盖生物科技有限公司 | A kind of Chinese and western medicinal composition preparation method for treating chronic gastric ulcer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035090A1 (en) * | 2002-10-16 | 2004-04-29 | Orexo Ab | Gastric acid secretion inhibiting composition |
| CN1500497A (en) * | 2002-11-14 | 2004-06-02 | 成都尚科药业有限公司 | Preparation method of compound soft capsule of traditional Chinese medicine and use |
| CN1504185A (en) * | 2002-11-28 | 2004-06-16 | 中外制药株式会社 | Pharmaceutical composition |
| CN105582428A (en) * | 2014-12-25 | 2016-05-18 | 耿福能 | Transdermal patch for acupoint sticking therapy and preparation method thereof |
-
2016
- 2016-06-17 CN CN201610437162.0A patent/CN105944104B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035090A1 (en) * | 2002-10-16 | 2004-04-29 | Orexo Ab | Gastric acid secretion inhibiting composition |
| CN1500497A (en) * | 2002-11-14 | 2004-06-02 | 成都尚科药业有限公司 | Preparation method of compound soft capsule of traditional Chinese medicine and use |
| CN1504185A (en) * | 2002-11-28 | 2004-06-16 | 中外制药株式会社 | Pharmaceutical composition |
| CN105582428A (en) * | 2014-12-25 | 2016-05-18 | 耿福能 | Transdermal patch for acupoint sticking therapy and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 汪陆玲: "刘爱民教授对丁桂散新用"煨脓祛腐"作用探讨", 《中医外治杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108653381A (en) * | 2018-07-11 | 2018-10-16 | 合肥华盖生物科技有限公司 | A kind of Chinese and western medicinal composition preparation method for treating chronic gastric ulcer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105944104B (en) | 2018-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI654987B (en) | Combination of valerian root extract and lavender oil for the treatment of sleep disorders | |
| CN102430090A (en) | Traditional Tibetan medicine Ruyizhenbao composite preparation and preparation method thereof | |
| CN103520293A (en) | Oral traditional Chinese medicine for improving and treating constipation | |
| CN102106965B (en) | Composition for treating acute injury of soft tissue and application thereof | |
| CN115531460A (en) | A kind of traditional Chinese medicine composition and its application in the preparation of hyperuricemia medicine | |
| CN102048841B (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN103690582A (en) | Composition containing dendrobium polysaccharide and atractylodes oil and application thereof | |
| JP2007008965A (en) | Hair growing agent | |
| CN105944104A (en) | Pharmaceutical composition for treating digestive tract ulcer | |
| CN100506225C (en) | Pharmaceutical use, medicine composition and preparation process of angelica oil components | |
| CN105535533A (en) | Traditional Chinese medicine composition for treatinggastritis | |
| CN100512796C (en) | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method | |
| CN100443073C (en) | Chinese Apea Ear-ring preparation capable of improving drug effect and preparation method thereof | |
| CN106581236A (en) | Medicinal composition for promoting gastric motility, and preparation method and application thereof | |
| CN104605344A (en) | Health food for enhancing immunity and preparation method of health food | |
| CN106421630A (en) | Radix Curcumae Aromaticae extract product, and preparation method and application thereof | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni | |
| CN112316125B (en) | Traditional Chinese medicine composition based on hirudin and preparation method of micropills thereof | |
| CN102846711B (en) | 'Shen Gui ' capsule is preparing the application in antithrombotic reagent | |
| CN102688254B (en) | Medicinal composition for treating chronic diarrhea and preparation method and use thereof | |
| CN102475781B (en) | Method for preparing traditional Chinese medicine composition used for treating essential hypertension | |
| CN102475780B (en) | Preparation method for traditional Chinese drug composition for treating primary hypertension | |
| CN100553616C (en) | A kind of medicine for the treatment of diabetes | |
| CN102475784B (en) | Chinese medicinal composition for treating essential hypertension and its preparation method | |
| CN102475785B (en) | Preparation method of Chinese medicinal composition for treating essential hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |